Ilyas Åahin

List of Publications by Year
in descending order

53	1,139	566801 15	414034 32
papers	citations	h-index	g-index

56	56	56	2152
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A pancancer analysis of impact of MDM2/MDM4 on immune checkpoint blockade (ICB).. Journal of Clinical Oncology, 2022, 40, 2630-2630.	0.8	2
2	Impact of metastasectomy for extrahepatic disease in stage IV colon cancer: A retrospective cohort NCDB analysis.. Journal of Clinical Oncology, 2022, 40, e15548-e15548.	0.8	0
3	Hyperprogression of a mismatch repair-deficient colon cancer in a humanized mouse model following administration of immune checkpoint inhibitor pembrolizumab. Oncotarget, 2021, 12, 2131-2146.	0.8	3
4	Strategies to sensitize cancer cells to immunotherapy. Human Vaccines and Immunotherapeutics, 2021, 17, 2595-2601.	1.4	9
5	3D tissue engineered plasma cultures support leukemic proliferation and induces drug resistance. Leukemia and Lymphoma, 2021, 62, 1-9.	0.6	5
6	A pilot study of 3D tissue-engineered bone marrow culture as a tool to predict patient response to therapy in multiple myeloma. Scientific Reports, 2021, 11, 19343.	1.6	6
7	Detection of clonotypic DNA in the cerebrospinal fluid as a marker ofÂcentral nervous system invasion in lymphoma. Blood Advances, 2021, 5, 5525-5535.	2.5	18
8	Therapeutic Targeting of Alternative RNA Splicing in Gastrointestinal Malignancies and Other Cancers. International Journal of Molecular Sciences, 2021, 22, 11790.	1.8	13
9	3D Tissue-Engineered Bone Marrow Culture Predicts Patient Response to Drugs in Multiple Myeloma. Blood, 2021, 138, 2690-2690.	0.6	0
10	The Role of Immune Checkpoint Blockade in the Hepatocellular Carcinoma: A Review of Clinical Trials. Frontiers in Oncology, 2021, 11, 801379.	1.3	21
11	AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing. Cell Death Discovery, 2020, 6, 57.	2.0	41
12	Asciminib in Relapsed Chronic Myeloid Leukemia. New England Journal of Medicine, 2020, 382, 1378-1379.	13.9	3
13	Cerebrospinal Fluid (CSF) Analysis of Tumor-Specific Cell-Free DNA (cfDNA) As a Diagnostic and Prognostic Tool for Central Nervous System (CNS) Invasion in Lymphoma. Blood, 2020, 136, 21-22.	0.6	5
14	MEK inhibitors reduce cellular expression of ACE2, pERK, pRb while stimulating NK-mediated cytotoxicity and attenuating inflammatory cytokines relevant to SARS-CoV-2 infection. Oncotarget, 2020, 11, 4201-4223.	0.8	22
15	Soy Isoflavones in Integrative Oncology: Increased Efficacy and Decreased Toxicity of Cancer Therapy. Integrative Cancer Therapies, 2019, 18, 153473541983531.	0.8	43
16	Clonal haematopoiesis of indeterminate potential among cancer survivors exposed to myelotoxic chemotherapy. British Journal of Haematology, 2019, 186, e31-e35.	1.2	17
17	Glycogen synthase kinase-3 beta inhibitors as novel cancer treatments and modulators of antitumor immune responses. Cancer Biology and Therapy, 2019, 20, 1047-1056.	1.5	59
18	Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma . OncoTargets and Therapy, 2019, Volume 12, 1085-1094.	1.0	48

#	Article	IF	Citations
19	Erythrophagocytosis on bone marrow found in severe autoimmune hemolytic anemia with reticulocytopenia. Blood, 2019, 134, 1877-1877.	0.6	3
20	Citron Rho-interacting kinase silencing causes cytokinesis failure and reduces tumor growth in multiple myeloma. Blood Advances, 2019, 3, 995-1002.	2.5	15
21	Androgen receptor-independent prostate cancer: an emerging clinical entity. Cancer Biology and Therapy, 2018, 19, 347-348.	1.5	7
22	Refractoriness to red blood cell transfusion therapy due to hypersplenism. Transfusion, 2018, 58, 2513-2516.	0.8	6
23	Recipients of Myelotoxic Chemotherapy Have Increased Prevalence of Clonal Hematopoiesis of Indeterminate Potential (CHIP) with a Typical Distribution of Chip-Associated Mutations. Blood, 2018, 132, 3841-3841.	0.6	1
24	Drug Delivery Approaches for the Treatment of Cervical Cancer. Pharmaceutics, 2016, 8, 23.	2.0	65
25	Targeting vasculogenesis to prevent progression in multiple myeloma. Leukemia, 2016, 30, 1103-1115.	3.3	46
26	CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation. Cell Reports, 2015, 12, 622-635.	2.9	123
27	Distinct roles of class I PI3K isoforms in multiple myeloma cell survival and dissemination. Blood Cancer Journal, 2014, 4, e204-e204.	2.8	11
28	Targeting survival and cell trafficking in multiple myeloma and <scp>W</scp>aldenstrom macroglobulinemia using panâ€class <scp>I PI</scp>3<scp>K</scp> inhibitor, buparlisib. American Journal of Hematology, 2014, 89, 1030-1036.	2.0	14
29	Role of endothelial progenitor cells in cancer progression. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 26-39.	3.3	70
30	WaldenstrÃ¶m macroglobulinemia: from biology to treatment. Expert Review of Hematology, 2014, 7, 157-168.	1.0	16
31	CXCR7-dependent angiogenic mononuclear cell trafficking regulates tumor progression in multiple myeloma. Blood, 2014, 124, 1905-1914.	0.6	32
32	The sialyltransferase ST3GAL6 influences homing and survival in multiple myeloma. Blood, 2014, 124, 1765-1776.	0.6	97
33	Pyk2 promotes tumor progression in multiple myeloma. Blood, 2014, 124, 2675-2686.	0.6	51
34	C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma. Blood, 2014, 123, 4120-4131.	0.6	187
35	Citron Rho-Interacting Serine/Threonine kinase (CIT) Is a Novel Therapeutic Target in Multiple Myeloma Cells. Blood, 2014, 124, 3430-3430.	0.6	0
36	Early Trafficking of Bone Marrow Derived-Endothelial Progenitor Cells Promotes Multiple Myeloma Progression. Blood, 2014, 124, 4719-4719.	0.6	0

#	Article	IF	Citations
37	Proline-Rich Tyrosine Kinase (Pyk2) Promotes Tumor Progression in Multiple Myeloma (MM) and Represents a Novel Target for Therapy in MM. Blood, 2014, 124, 2101-2101.	0.6	0
38	Outcomes of locally advanced breast cancer patients with â‰¥10 positive axillary lymph nodes. Medical Oncology, 2013, 30, 615.	1.2	22
39	The influence of hypoxia on CML trafficking through modulation of CXCR4 and E-cadherin expression. Leukemia, 2013, 27, 961-964.	3.3	17
40	Lin28B/Let-7 Axis Regulates Multiple Myeloma Proliferation By Enhancing c-Myc and Ras Survival Pathways. Blood, 2013, 122, 273-273.	0.6	3
41	CXCR4 Is a Regulator Of Disease Involvement Of Extramedullary Myeloma Confirmed By a Novel Mouse Model For Extramedullary Disease. Blood, 2013, 122, 5320-5320.	0.6	1
42	Bone Marrow Mobilization Of Endothelial Progenitor Cells Represents An Early Pathogenic Event During Multiple Myeloma Progression. Blood, 2013, 122, 680-680.	0.6	4
43	Proline-Rich Tyrosine Kinase (Pyk2) Promotes Tumor Progression In Multiple Myeloma Through Modulation Of Wnt/Î²-Catenin Signaling Pathway. Blood, 2013, 122, 3094-3094.	0.6	0
44	Mirna Expression Profiling and Proteomic Analysis Of Circulating Exosomes From Multiple Myeloma Patients. Blood, 2013, 122, 3086-3086.	0.6	2
45	Class I PI3K Isoforms Exert a Differential Role On Survival and Cell Trafficking In Multiple Myeloma. Blood, 2013, 122, 3159-3159.	0.6	0
46	Silencing The Sialyltransferase Gene ST3GAL6 Inhibits Adhesion and Migration Of Myeloma Cells In Vitro and Reduces The Homing and Proliferation Of Tumor Cells In Vivo. Blood, 2013, 122, 275-275.	0.6	0
47	Metabolomic Profiling Identifies Mechanisms Regulating Hypoxia-Induced Drug Resistance in Multiple Myeloma. Blood, 2012, 120, 3944-3944.	0.6	0
48	Sequential taxane and anthracycline-containing neo-adjuvant regimens; any rationale behind the sequence?. Breast, 2011, 20, 291.	0.9	0
49	Aspirin intake may prevent metastasis in patients with triple-negative breast cancer. Medical Oncology, 2011, 28, 1308-1310.	1.2	4
50	How can Nolvadex abolish arthralgia in women taking newer generic Tamoxifen preparations?. Breast, 2010, 19, 436.	0.9	1
51	Mechanisms behind the antiâ€tumour effects of zoledronic acid use in multiple myeloma. British Journal of Haematology, 2010, 151, 530-531.	1.2	1
52	Management of polyorchidism: Surgery or conservative management?. Journal of Human Reproductive Sciences, 2010, 3, 162.	0.4	9
53	Possible mechanisms behind taxaneâ€“anthracycline sequencing. Lancet Oncology, The, 2010, 11, 514-515.	5.1	2